{"altmetric_id":11880233,"selected_quotes":["$LXRX Phase 3 trial w\/est Sep completion date NCT02421510: Trial Tracker"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Lexicon Pharmaceuticals"],"first_seen_on":"2016-09-07T13:05:20+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1498149173,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421510","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421510?term=inTandem2&rank=1","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421510?term=sotagliflozin&phase=2&rank=4","https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02421510"],"nct_id":"NCT02421510","pubdate":"2015-04-15T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem2)","type":"clinical_trial_study_record"},"altmetric_score":{"score":16.75,"score_history":{"1y":14.25,"6m":7,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":16.75},"context_for_score":{"all":{"total_number_of_other_articles":8409255,"mean":7.0791347310873,"rank":527532,"this_scored_higher_than_pct":93,"this_scored_higher_than":7880540,"rank_type":"exact","sample_size":8409255,"percentile":93},"similar_age_3m":{"total_number_of_other_articles":253142,"mean":12.489010496126,"rank":26047,"this_scored_higher_than_pct":89,"this_scored_higher_than":227024,"rank_type":"exact","sample_size":253142,"percentile":89},"this_journal":{"total_number_of_other_articles":24768,"mean":10.533192231598,"rank":1793,"this_scored_higher_than_pct":92,"this_scored_higher_than":22972,"rank_type":"exact","sample_size":24768,"percentile":92},"similar_age_this_journal_3m":{"total_number_of_other_articles":969,"mean":11.346791322314,"rank":72,"this_scored_higher_than_pct":92,"this_scored_higher_than":897,"rank_type":"exact","sample_size":969,"percentile":92}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}},"geo":{"twitter":{"US":1}}},"counts":{"total":{"posts_count":6},"news":{"unique_users_count":2,"unique_users":["medscape","seeking_alpha"],"posts_count":4},"twitter":{"unique_users_count":1,"unique_users":["fda_tracker"],"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["450445314973329"],"posts_count":1}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/fda_tracker\/statuses\/773507369472888832","license":"gnip","citation_ids":[11880233],"posted_on":"2016-09-07T13:05:02+00:00","author":{"name":"FDA Tracker","url":"http:\/\/www.fdatracker.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1667207308\/square_logo_normal.png","description":"Analytics for Pharma and Biotech Traders","id_on_source":"fda_tracker","tweeter_id":"391492257","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2972},"tweet_id":"773507369472888832"}],"news":[{"title":"Novel SGLT Inhibitor Adds Benefit to Insulin in Type 1 Diabetes","url":"http:\/\/ct.moreover.com\/?a=27944713659&p=1pl&v=1&x=_qTG3ZaZsbFU9HCGrNtzPg","license":"public","citation_ids":[11896837,11880233,4685901],"posted_on":"2016-09-13T18:15:17+00:00","summary":"Top-line results show some promise for a completely new, but still investigational, oral agent, sotagliflozin, in people with type 1 diabetes.","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Lexicon Pharma's sotagliflozin successful in second late-stage study in type 1 diabetics; shares up 13% premarket","url":"http:\/\/ct.moreover.com\/?a=28976735756&p=1pl&v=1&x=SxFsTz-48GgHEOvhfH8AGw","license":"public","citation_ids":[11896837,11880233,4685901],"posted_on":"2016-12-21T12:21:26+00:00","summary":"A second Phase 3 clinical trial, Tandem2, assessing Lexicon Pharmaceuticals' (NASDAQ: LXRX ) orally administered sotagliflozin in adult type 1 diabetics met its primary endpoint of statistically significantly lowering HbA1c after 24 weeks of\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Sotagliflozin Meets End Point in Second Type 1 Diabetes Trial","url":"http:\/\/ct.moreover.com\/?a=29004614765&p=1pl&v=1&x=RcsGk6jF99eW-baikvhJWA","license":"public","citation_ids":[11896837,11880233,4685901],"posted_on":"2016-12-23T19:49:27+00:00","summary":"A second randomized clinical trial suggests that the novel investigational agent sotagliflozin could be an effective adjunct to insulin therapy in patients with type 1 diabetes.","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"SGLT1\/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 Diabetes","url":"http:\/\/ct.moreover.com\/?a=30983819213&p=1pl&v=1&x=rPZsyCWp62A3Cg42sac5aQ","license":"public","citation_ids":[11896837,11880233,4685901],"posted_on":"2017-06-22T16:32:53+00:00","summary":"SAN DIEGO \u2014 Discussing data on the investigational oral agent sotagliflozin \u2014 a first-in-class, oral dual inhibitor of both sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) \u2014 for the treatment of type 1 diabetes, doctors at the American\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}}],"facebook":[{"title":"A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone - Full Text View - ClinicalTrials.gov","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1538242879526895&id=450445314973329","license":"public","citation_ids":[11896837,11880233,4685901],"posted_on":"2017-01-01T10:08:24+00:00","summary":"\u0e40\u0e23\u0e34\u0e48\u0e21\u0e15\u0e49\u0e19\u0e1b\u0e35\u0e42\u0e14\u0e22\u0e01\u0e32\u0e23\u0e41\u0e19\u0e30\u0e19\u0e33\u0e43\u0e2b\u0e49\u0e23\u0e39\u0e49\u0e08\u0e31\u0e01\u0e22\u0e32\u0e43\u0e2b\u0e21\u0e48\u0e01\u0e31\u0e19\u0e04\u0e23\u0e31\u0e1a\n\n\"Sotagliflozin\" \u0e22\u0e32\u0e43\u0e2b\u0e21\u0e48\u0e17\u0e35\u0e48\u0e2d\u0e32\u0e08\u0e43\u0e0a\u0e49\u0e43\u0e19 type 1 DM \n \n\u0e15\u0e2d\u0e19\u0e19\u0e35\u0e49\u0e21\u0e35\u0e1c\u0e25\u0e17\u0e35\u0e48\u0e40\u0e1b\u0e47\u0e19 randomized clinical trial \u0e2d\u0e2d\u0e01\u0e21\u0e32 \u0e17\u0e35\u0e48\u0e1e\u0e1a\u0e27\u0e48\u0e32\u0e40\u0e1b\u0e47\u0e19 effective adjunct treatment \u0e01\u0e31\u0e1a insulin therapy \u0e43\u0e19 T1DM\n\n\u0e21\u0e32\u0e17\u0e33\u0e04\u0e27\u0e32\u0e21\u0e23\u0e39\u0e49\u0e08\u0e31\u0e01\u0e01\u0e31\u0e19\u0e2b\u0e19\u0e48\u0e2d\u0e22\u0e09\u0e25\u0e2d\u0e07\u0e1b\u0e35\u0e43\u0e2b\u0e21\u0e48\u0e04\u0e23\u0e31\u0e1a\n\nSotagl","author":{"name":"Endocrinology by Prof. Chatlert Pongchaiyakul","url":"https:\/\/www.facebook.com\/450445314973329","facebook_wall_name":"Endocrinology by Prof. Chatlert Pongchaiyakul","image":"https:\/\/graph.facebook.com\/450445314973329\/picture","id_on_source":"450445314973329"}}]}}